FUSED PYRROLOPYRIDINE DERIVATIVE
Disclosed is a fused pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular a pharmaceutical composition for prevention or treatment of diseases that are caused by undesirable cytokine signaling or diseases that are caused by abnormal cytok...
Saved in:
Main Authors | , , , , , , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
18.11.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Disclosed is a fused pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular a pharmaceutical composition for prevention or treatment of diseases that are caused by undesirable cytokine signaling or diseases that are caused by abnormal cytokine signaling. The inventors have intensively studied on compounds having JAK inhibitory activity, and found that the compound of the present invention, namely a fused pyrrolopyridine derivative has excellent JAK inhibitory activity and is thus useful as an agent for prevention or treatment of diseases that are caused by undesirable cytokine signaling or diseases that are caused by abnormal cytokine signaling.
La presente invención proporciona un derivado de pirrolopiridina condensado que es útil como ingrediente activo para una composición farmacéutica, particularmente, una composición farmacéutica para prevenir o tratar las enfermedades causadas por la transducción de señal de citosina indeseable o enfermedades causadas por la transducción de señal de citosina anormal. Los presentes inventores han estudiado ampliamente un compuesto que tiene una acción inhibitoria de JAK, y por lo tanto, han encontrado que un derivado de pirrolopiridina condensado, que es el compuesto de la presente invención, tiene una acción inhibitoria excelente de JAK, y por lo tanto, es útil como un agente para prevenir o tratar las enfermedades causadas por la transducción de señal de citosina indeseable o enfermedades causadas por la transducción de señal de citosina anormal, de tal modo se completa la presente invención. |
---|---|
Bibliography: | Application Number: MX20110010923 |